These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9869495)

  • 1. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs.
    Thomas CV; McDaniel GM; Holzgrefe HH; Mukherjee R; Hird RB; Walker JD; Hebbar L; Powell JR; Spinale FG
    J Cardiovasc Pharmacol; 1998 Dec; 32(6):902-12. PubMed ID: 9869495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: effects on ventricular and myocyte function.
    Spinale FG; Holzgrefe HH; Walker JD; Mukherjee R; Kribbs SB; Powell JR; Antonaccio M
    J Cardiovasc Pharmacol; 1997 Nov; 30(5):623-31. PubMed ID: 9388045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: differential effects on myocyte contractile processes.
    Spinale FG; Holzgrefe HH; Mukherjee R; Webb ML; Hird RB; Cavallo MJ; Powell JR; Koster WH
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1082-94. PubMed ID: 9399980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function.
    Spinale FG; Holzgrefe HH; Mukherjee R; Hird RB; Walker JD; Arnim-Barker A; Powell JR; Koster WH
    Circulation; 1995 Aug; 92(3):562-78. PubMed ID: 7634471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular basis for improved left ventricular pump function after digoxin therapy in experimental left ventricular failure.
    McMahon WS; Holzgrefe HH; Walker JD; Mukherjee R; Arthur SR; Cavallo MJ; Child MJ; Spinale FG
    J Am Coll Cardiol; 1996 Aug; 28(2):495-505. PubMed ID: 8800131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chronic angiotensin-converting enzyme inhibition on left ventricular and myocyte structure and function during recovery from chronic rapid pacing.
    Melton DM; Holzgrefe HH; Walker JD; Mukherjee R; Arthur SR; Antonaccio MJ; Koster WH; Spinale FG
    J Mol Cell Cardiol; 1997 Feb; 29(2):697-710. PubMed ID: 9140827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
    Spinale FG; Mukherjee R; Iannini JP; Whitebread S; Hebbar L; Clair MJ; Melton DM; Cox MH; Thomas PB; de Gasparo M
    Circulation; 1997 Oct; 96(7):2397-406. PubMed ID: 9337216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
    Birner C; Ulucan C; Bratfisch M; Götz T; Dietl A; Schweda F; Riegger GA; Luchner A
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Nov; 385(11):1117-25. PubMed ID: 22895639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry.
    McElmurray JH; Mukherjee R; New RB; Sampson AC; King MK; Hendrick JW; Goldberg A; Peterson TJ; Hallak H; Zile MR; Spinale FG
    J Pharmacol Exp Ther; 1999 Nov; 291(2):799-811. PubMed ID: 10525103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition.
    Mellin V; Jeng AY; Monteil C; Renet S; Henry JP; Thuillez C; Mulder P
    J Cardiovasc Pharmacol; 2005 Sep; 46(3):390-7. PubMed ID: 16116347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caspase inhibition attenuates contractile dysfunction following cardioplegic arrest and rewarming in the setting of left ventricular failure.
    Yarbrough WM; Mukherjee R; Squires CE; Reese ES; Leiser JS; Stroud RE; Sample JA; Hendrick JW; Mingoia JT; McLean JE; Hardin AE; Dowdy KB; Spinale FG
    J Cardiovasc Pharmacol; 2004 Dec; 44(6):645-50. PubMed ID: 15550782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
    Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
    Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative and selective effects of propofol on isolated swine myocyte contractile function in pacing-induced congestive heart failure.
    Hebbar L; Dorman BH; Clair MJ; Roy RC; Spinale FG
    Anesthesiology; 1997 Mar; 86(3):649-59. PubMed ID: 9066332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure.
    Cha YM; Redfield MM; Shah S; Shen WK; Fishbein MC; Chen PS
    Heart Rhythm; 2005 Sep; 2(9):984-90. PubMed ID: 16171755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
    Pu Q; Larouche I; Schiffrin EL
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: cellular mechanisms of action.
    Spinale FG; Iannini JP; Mukherjee R; Melton DM; de Gasparo M
    J Card Fail; 1998 Dec; 4(4):325-32. PubMed ID: 9924854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopeptidase inhibition in a canine model of exercise-induced left ventricular dysfunction.
    Holzgrefe HH; Arthur SR; Powell JR
    Clin Exp Pharmacol Physiol; 2002 Aug; 29(8):696-703. PubMed ID: 12100002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct effects of chronic beta-adrenergic receptor blockade on left ventricular and myocyte function in a model of tachycardia-induced congestive heart failure.
    Spinale FG; Johnson WS; Wang Y; Wang Z; Mukherjee R; Hebbar L; Jones BU
    J Card Fail; 1996 Dec; 2(4):311-8. PubMed ID: 8989646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular and myocyte structure and function following chronic ventricular tachycardia in rabbits.
    Spinale FG; Eble DM; Mukherjee R; Johnson WS; Walker JD
    Basic Res Cardiol; 1994; 89(5):456-67. PubMed ID: 7702537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.